| 產(chǎn)品編號(hào) | bs-43042P |
| 英文名稱(chēng) | Recombinant SARS-Cov-2 Spike S1 protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y), His (HEK293) |
| 中文名稱(chēng) | 重組SARS冠狀病毒2 Spike突變蛋白S1(SARS-CoV-2 spike protein; 2019-nCOV Spike protein; Spike glycoprotein; Spike protein S1; Surface glycoprotein; Spike protein RBD; SPIKE_SARS2; 2019-nCOV Spike S1(L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y), Recombinan |
| 別 名 | SARS-CoV-2 spike protein; 2019-nCOV Spike protein; Spike glycoprotein; Spike protein S1; Surface glycoprotein; Spike protein RBD; SPIKE_SARS2; 2019-nCOV Spike S1(L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y), Recombinant (His Tag). ;Recombinant SARS-Cov-2 Spike S1 protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y), His (HEK293) 新冠病毒S蛋白; 新冠S蛋白; 新冠S1蛋白; SARS-CoV-2 S1蛋白; |
| 理論分子量 | 73kDa |
| 檢測(cè)分子量 | 120-140 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | ＞0.5 mg/ml |
| 物 種 | SARS-Cov-2 |
| 序 列 | 14-685/1273 |
| 純 度 | >90% as determined by SDS-PAGE |
| 純化方法 | AC |
| 內(nèi)毒素 | Not analyzed |
| 表達(dá)系統(tǒng) | HEK293 cell |
| 活性 | Yes |
| 標(biāo)簽 | His |
| 緩 沖 液 | PBS (pH7.4). |
| 保存條件 | Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. SWISS: P0DTC2 Gene ID: 43740568 |
| 產(chǎn)品圖片 |
The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.
The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.
|
